News

Halozyme Therapeutics has expanded its global collaboration and licence agreement with argenx to develop and commercialise subcutaneous formulations for two additional exclusive targets using its ENHANZE® drug delivery technology.

Italfarmaco S.p.A. and VeriSIM Life have entered into a strategic collaboration to discover and develop novel histone deacetylase (HDAC)-targeted therapies for neuromuscular, fibrotic and rare diseases.

Immunome has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for IM-1340, an investigational antibody-drug conjugate (ADC) being developed for advanced solid tumours

AbbVie has partnered with Valkai to expand the use of AI across selected areas of clinical development.

Turbine and Daiichi Sankyo have expanded their collaboration to support antibody-drug conjugate (ADC) discovery using computational modelling.

Pretzel Therapeutics has received Fast Track Designation from the US Food and Drug Administration (FDA) for PX578, an investigational treatment for POLG-mediated primary mitochondrial disorders, also known as POLG disease.

PTC Therapeutics has completed its previously announced agreement with Sangamo Therapeutics to acquire ST-920 (isaralgagene civaparvovec), a one-time AAV gene therapy candidate being developed for Fabry disease.

Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients

Eisai and Biogen have received approval in Japan for LEQEMBI Pen, a subcutaneous (SC) formulation of lecanemab, for the treatment of early Alzheimer’s disease (AD).

VaxThera S.A.S., a Colombian biotechnology company developing and manufacturing vaccines and biological products, has entered into an agreement with Codagenix Inc. to exclusively license